Classes
Publications
- Recommendations for the diagnosis and treatment of chronic lymphocytic leukaemia (CLL)2013 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: analysis of 1287 diagnostic and 1148 follow-up CLL samples2011 | Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis2011 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation2010 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia2008 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Quantitation of minimal residual disease in patients with chronic lymphocytic leukemia using locked nucleic acid-modified, fluorescently labeled hybridization probes and real-time PCR technology2007 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- ZAP-70 in B-cell chronic lymphocytic leukemia: clinical significance and methods of detection2006 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Chemobrain in blood cancers: How chemotherapeutics interfere with the brain's structure and functionality, immune system, and metabolic functions2024 | Third Faculty of Medicine, Central Library of Charles University
- Cognitive impairment associated with Hodgkin's lymphoma and chemotherapy2023 | First Faculty of Medicine, Third Faculty of Medicine
- Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis2023 | First Faculty of Medicine, Third Faculty of Medicine
Loading network view...